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Abstract The serpin plasminogen activator inhibitor-1 (PAI-1), 
an important risk factor for thrombotic disease can be 
neutralized by distinct mechanisms. We hypothesized that the 
combination of two compounds, with PAI-1 neutralizing proper-
ties based on different mechanisms, may result in a synergistic 
effect. Therefore, seven monoclonal antibodies with PAI-1 
neutralizing properties were pairwise evaluated for the possible 
presence of synergistic or antagonistic effects. Out of 21 
combinations, three particular combinations, i.e. MA-33H1/ 
MA-33B8, MA-33B8/MA-7D4B7, and MA-7D4B7/MA-33H1 
exhibited strong synergistic effects in comparison with their 
properties when evaluated individually. The observed synergism 
resulted in a maximum enhancement between 2- and 5-fold 
(P<0.05, vs. theoretically expected effect calculated based on 
additive effects). Strikingly, synergism was only observed 
between monoclonal antibodies directed against different epi-
topes and with different molecular mechanisms of PAI-1 
neutralization. This phenomenon of synergism opens new 
perspectives in the design of therapeutic or preventive strategies 
aimed at enhancing endogenous fibrinolysis through modulation 
of PAI-1 activity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Plasminogen activator inhibitor-1 (PAI-1), a member of the 
superfamily of serine proteinase inhibitors (serpins), is the 
primary physiological inhibitor of both tissue-type plasmino-
gen activator (t-PA) and urokinase-type plasminogen activa-
tor (u-PA). PAI-1 exhibits a unique conformational flexibility 
and can occur as an active, latent or substrate conformation 
[1,2]. Since elevated levels of PAI-1 are associated with an 
increased risk of several important thrombotic deceases [3,4], 
development of strategies aimed at the inhibition of PAI-1 
may be useful to prevent thrombosis or to enhance endoge-
nous fibrinolysis. Several studies have indicated the potential 
clinical use of agents that inhibit PAI-1 activity. Enhancement 
of fibrinolysis, both in vivo and in vitro, has been reported by 
the inhibition of PAI-1 with polyclonal antibody fragments 
[5,6] or with monoclonal antibodies [7,8]. 
Antibodies might neutralize PAI-1 activity through at least 
three different mechanisms: (1) direct interaction with the re-
active site loop; (2) enhancing the conversion of active to 
latent PAI-1; (3) switching active PAI-1 to substrate PAI-1. 
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We hypothesized that combination of two monoclonal anti-
bodies, with neutralizing properties towards PAI-1 based on 
two different mechanisms, might result in a synergistic activ-
ity. Therefore we evaluated seven monoclonal antibodies (with 
PAI-1 neutralizing properties) for possible synergistic interac-
tions upon pairwise combination. Various methods, com-
monly used for evaluation of synergism or antagonism and 
well described in the pharmacological literature [9-11], such as 
effect summation, isoboles and the interaction index, were 
applied. Three monoclonal antibodies, each inhibiting PAI-1 
by a distinct mechanism, were found to act strongly synergisti-
cally (P < 0.05) in the three possible combinations evaluated. 
These data confirm our hypothesis that, because of its unique 
conformational flexibility, synergism in neutralization of PAI-
1 activity may play an important role and could be taken into 
account in the development of PAI-1 inhibitory compounds 
and/or in the design of therapeutic strategies for pharmaco-
logical suppression of PAI-1 activity. 
2. Materials and methods 
2.1. Materials 
Human t-PA (predominantly in the single-chain form) was a kind 
gift from Boehringer Ingelheim (Brussels, Belgium). Chromogenic 
substrate S-2403 was obtained from Kabi Vitrum (Stockholm, Swe-
den). Recombinant human PAI-1 (expressed in E. coli) was prepared 
as described [12]. Monoclonal antibodies were raised against human 
PAI-1 as described previously: MA-7D4B7 [13,14], MA-7F5C12 
[13,14], MA-8H9D4 [15], MA-33B8 [15], MA-33H1 [15], MA-55F4 
and MA-56A7C10 [15]. This set of inhibitory monoclonal antibodies 
represent seven different epitopes [13-16] and exert their PAI-1 inhib-
itory properties through, at least, three distinct mechanisms [15,16]. 
96-well polystyrene microtiter plates were purchased from Costar 
(Cambridge, MA). 
2.2. PAI-1 activity assay 
PAI-1 activity was determined using the method as described by 
Verheijen et al. [17]. In brief, PAI-1 containing samples (50 μΐ) in Tris-
bufTered saline (0.1 M NaCl, 0.05 M Tris/HCl, pH 7.4, containing 
0.01% Tween 80; TBS) were mixed with an equal volume of t-PA 
(20 U/ml) in TBS and incubated for 15 min at 37°C. Subsequently, 
100 μΐ of a solution containing plasminogen (1 μΜ), CNBr-digested 
fibrinogen (1 uM) and S-2403 (0.6 mM) were added. Residual t-PA 
was then quantitated by measuring the absorbance at 405 nm. One 
unit of PAI-1 is defined as the amount of PAI-1 required to neutralize 
one international unit of t-PA. 
2.3. PAI-1 neutralization assay 
Based on previous experiments carried out to evaluate the influence 
of monoclonal antibodies on the activity of human PAI-1 [14,15], 
seven monoclonal antibodies were selected to study possible synergis-
tic effects. Neutralization of PAI-1 activity by monoclonal antibodies 
was determined as described [15], and based on quantitàtion of resid-
ual PAI-1 activity after preincubation of PAI-1 with different concen-
trations of monoclonal antibodies. Briefly, 100 μΐ PAI-1 (50 ng/ml) 
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were incubated either with 100 μΐ buffer (TBS) or with 100 μΐ of a 
solution containing purified monoclonal antibodies at the indicated 
concentration. After incubation of this mixture for 25 min at 37°C, 
residual PAI-1 activity was quantitated with the PAI-1 activity assay 
as described above. The percentage inhibition (i.e. neutralization of 
PAI-1 activity) was then calculated based on the ratio of the PAI-1 
activity in the presence versus the absence of antibodies. 
2.4. Evaluation of synergism 
Two methods were applied for evaluation of synergism [9-11], effect 
summation and isoboles in combination with calculation of the inter-
action index. 
Firstly, if Ei, E2 and E1+2 represent the effect (i.e. extent of PAI-1 
neutralization) of monoclonal antibody 1, monoclonal antibody 2 and 
a combination of both, respectively, then synergism is present when 
Ei+2 > Ei+E2. The effect summation approach was applied as follows. 
A theoretical dose-response curve ('Ei+E2'), was constructed based on 
the two respective individual dose-response curves and was subse-
quently compared with the experimental dose-response curves ob-
tained for the equimolar combination of the two antibodies. Alterna-
tively, an experimental dose-response curve obtained by varying the 
concentration of one antibody in the presence of a fixed concentration 
of another antibody was compared with the corresponding theoretical 
dose response based on the respective concentrations of the two anti-
bodies used. 
Secondly, the concentration, [MA l]e and [MA 2]e, of monoclonal 
antibody 1 and monoclonal antibody 2, respectively, that produce a 
predefined effect (i.e. 50% neutralization of PAI-1) was determined 
from individual dose-response curves. On the other hand dose-re-
sponse curves were constructed using particular combinations of 
two antibodies MA 1 and MA 2 (with the ratio MA 1 :MA 2 ranging 
between 0.02 and 22) and the concentrations ([MA l]c and [MA 2]c) 
of the respective antibodies in a particular combination required to 
produce the same effect were deduced. These data were then used to 
construct isoboles and to calculate the interaction index 
Int Ind = 
[MA l]c , [MA 2], 
+ [MA l]e [MA 2], 
2.5. Other methods 
Affinity constants of antibodies for PAI-1 or for PAI-1 saturated 
with another monoclonal antibody were determined as described pre-
viously using Biacore (Pharmacia, Upsala, Sweden) [15]. 
3. Results and discussion 
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Fig. 1. Inhibition of PAI-1 activity by an equimolar mixture of 
monoclonal antibodies. Theoretical dose-response curve (closed sym-
bol) and experimental dose-response curve (open symbol) of mix-
tures of two monoclonal antibodies (at equimolar ratio). A: MA-
33H1/MA-7D4B7; B: MA-33B8/MA-33H1; C: MA-7D4B7/MA-
33B8. Mean ± S.D., n = 3. 
In an initial phase of the study seven monoclonal antibod-
ies, MA-7D4B7, MA-7F5C12, MA-8H9D4, MA-33B8, MA-
33H1, MA-55F4 and MA-56A7C10 were evaluated, individu-
ally and as equimolar mixtures (i.e. 21 combinations) for their 
capacity to neutralize PAI-1 activity. The presence or absence 
of synergism was then deduced from the constructed dose-
response curves as analysed by the effect summation ap-
proach. 
Based on these data three pairs (i.e. MA-33B8/MA-33H1, 
MA-33B8/MA-7D4B7, MA-33H1/MA-7D4B7) clearly showed 
synergism as illustrated in Fig. 1. All other combinations ex-
hibited marginal synergism or no synergism (data not shown). 
Antagonism was never observed. It is interesting to note that 
these antibodies are directed against different epitopes. This 
observation is in keeping with the general view that synergism 
can only be observed between compounds exerting similar 
biological/pharmacological effects but through interaction 
with different targets. 
These three combinations were then subjected to a more 
detailed analysis. 
For each of these antibodies, dose-response curves were 
determined either in the absence or in the presence of a con-
stant amount of another antibody. The data represented in 
Fig. 2 show the pronounced synergy of the mixtures of a fixed 
amount of one antibody with different amounts of the other 
antibody. In the majority of the cases the difference between 
theoretically expected and experimentally observed effect is 
statistically significant (P<0.05) and reaches up to 5-fold 
(e.g. MA-33H1 and MA-7D4B7). Following the construction 
of various dose-response curves using these combinations at 
different ratios the isoboles as shown in Fig. 3 were obtained. 
From their concave shape it can again be concluded that these 
combinations are characterized by a functional synergism with 
respect to PAI-1 neutralization. The respective interaction in-
dices (Fig. 3 insets) are consistently lower than 1, further 
confirming the phenomena of synergism between these anti-
bodies. From the obtained data it is clear that these particular 
pairs of antibodies act synergistically on the neutralization of 
PAI-1 activity. A possible explanation for this synergism 
could be that binding of one antibody to PAI-1 would in-
crease the affinity of PAI-1 for the other antibody, thereby 
resulting in a steeper dose-response curve. To evaluate this 
possibility, the affinity constants of the individual antibody 
for binding to PAI-1 as such and to PAI-1 saturated with 
another antibody were determined. As can be deduced from 
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the data in Table 1 no major influence occurs, indicating that 
the observed synergism is not related to induced increases in 
affinities. 
Importantly all three antibodies inactivate PAI-1 by differ-
ent molecular mechanisms. MA-33H1 switches PAI-1 from an 
inhibitory molecule to a substrate-like molecule [15] and the 
epitope has been found to be located between amino acid Glu-
128 and Ala-156 of PAI-1 [18]. MA-33B8 most likely neutral-
izes PAI-1 activity through an enhanced conversion of active 
to latent PAI-1 ([15]; Shore, J. and Declerck, P.J., in prepa-
ration). MA-33B8 is directed against a conformational epi-
tope, not localized in the direct area of the reactive site 
loop. In contrast, MA-7D4B7 would inhibit PAI-1 through 
a direct interaction with the reactive site loop [14,16]. In this 
view and based on the known conformational flexibility of 
PAI-1 and its capacity to adopt various conformations with 
different functional properties, it could be speculated that the 
conformational change induced upon binding of one antibody 
makes PAI-1 more vulnerable to inhibition with the other 
antibody. 
In conclusion, combining different monoclonal antibodies 
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Fig. 3. Isoboles and interaction index of different combinations (at 
various ratios) of monoclonal antibodies. The graphs represent the 
molar excess of each antibody in a combination with a particular 
ratio MA 1:MA 2 (cfr methods), required to inhibit 50% of PAI-1 
activity. The insets show the obtained interaction index (Int Ind). 
A: MA-33H1/MA-7D4B7; B: MA-33B8/MA-33H1; C: MA-7D4B7/ 
MA-33B8. The straight line represents the graph that would have 
been obtained in case of the absence of synergism. 
that exhibit neutralizing properties towards PAI-1 through 
distinct molecular mechanisms, results in synergistic function-
al effects. Even though the underlying molecular mechanism 
responsible for this observation is not clear yet, the possibility 
of synergism between various PAI-1 modulating compounds 
should be considered in the design of therapeutic or preven-
tive strategies to interfere with PAI-1 activity. Indeed our 
observation also opens new perspectives in the search for 
low molecular weight compounds with PAI-1 inhibitory prop-
Fig. 2. Inhibition of PAI-1 activity by various concentrations of one 
monoclonal antibody in the presence of a fixed dose of another 
antibody. The hatched bars represent the theoretically expected val-
ue and the filled bars represent the experimental value. A: MA-
33H1/MA-7D4B7; B: MA-33B8/MA-33H1; C: MA-7D4B7/MA-
33B8. *: P<0.05, **: n.s., mean ± S.D., и = 3. 
Table 1 
Affinity constants (108 M_1) of the monoclonal antibodies for bind-
ing to PAI-1 (either pretreated or not) 
Pretreatment 
None 
MA-33H1 
MA-33B8 
MA-7D4B7 
Monoclonal 
MA-33H1 
15.1 
NA 
11.0 
2.2 
antibody 
MA-33B8 
9.0 
6.4 
NA 
2.5 
MA-7D4B7 
2.5 
1.4 
1.6 
NA 
NA: not applicable. 
Data represent mean value of two experiments. 
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erties: therapeutic application of such compounds may well 
benefit from a possible synergism since simultaneous admin-
istration of two synergistically acting compounds will allow to 
obtain the desired pharmacological effect at a much lower 
dose. Consequently a higher specificity may be obtained 
with much less pronounced side-effects. 
It is also important to note that, in contrast to the generally 
observed mechanism of synergism (i.e. involving interaction of 
two compounds with different target molecules), this is, to the 
best of our knowledge, the first report on synergism occurring 
through interaction of two compounds with the same target 
molecule. In the current study, the existence of this phenom-
enon, for which we propose the name 'intra-molecular syner-
gism', is most likely associated with the flexibility of the target 
molecule, i.e. PAI-1. Yet, it is interesting to speculate that a 
similar approach of 'intra-molecular synergism' may be appli-
cable for interference with the activity of other putative target 
proteins. 
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